Drug Trial Radar · NCT07759869
A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Jul 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this open-label phase 3 study is to evaluate the safety of HS-10380 on the incidence, severity, relationship to investigational product of adverse events (AE), serious adverse events (SAE), and adverse events leading to study drug discontinuationin Chinese adult participants with schizophrenia.
Conditions
- SCHIZOPHRENIA 1 (Disorder)
Interventions
HS-10380Drug
Oral;QD;W1:dose titration; W1-2:dose adjust to optimal level;Week 3-52:stable dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AE)Time frame: From first dose to end of study (Up to approximately 54 weeks )
- Incidence and severity of serious adverse events (SAE)Time frame: From first dose to end of study (Up to approximately 52 weeks)
- Incidence of Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug DiscontinuationTime frame: From first dose to end of study (Up to approximately 54 weeks )
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Sixth Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.